Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.
about
Status of hepatitis C virus vaccination: Recent updateBest strategies for global HCV eradication.In Silico Identification and Conservation Analysis of B-cell and T-Cell Epitopes of Hepatitis C Virus 3a Genotype Enveloped Glycoprotein 2 From Pakistan: A Step Towards Heterologous Vaccine DesignImmunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice.Enhanced-Transient Expression of Hepatitis C Virus Core Protein in Nicotiana tabacum, a Protein With Potential Clinical Applications.Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c miceA Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine.A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in MiceConstruction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposesHeterologous Expression of Hepatitis C Virus Core Protein in Oil Seeds of Brassica napus LImmunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer.Prospects for prophylactic hepatitis C vaccines based on virus-like particlesEnhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein ImmunizationVirus-like particle-based vaccines against hepatitis C virus infection.Peptides as the next generation of anti-infectives.Progress in the development of vaccines for hepatitis C virus infection.Biomedical applications of yeast- a patent view, part one: yeasts as workhorses for the production of therapeutics and vaccines.Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens.Design and expression of fusion protein consists of HBsAg and Polyepitope of HCV as an HCV potential vaccine.Co-expression of hepatitis C virus polytope-HBsAg and p19-silencing suppressor protein in tobacco leaves.Recombinant expression of the alternate reading frame protein (ARFP) of hepatitis C virus genotype 4a (HCV-4a) and detection of ARFP and anti-ARFP antibodies in HCV-infected patients.Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial).The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
P2860
Q26774612-53BD26FE-2C39-4138-A3B8-44EC9224786EQ27693824-5B0CA758-A28A-4BF1-95EA-718485BD38D1Q33808123-F5192381-6CAD-405D-82B2-AB8F37447840Q34546149-E7FD9685-1D02-4D6A-8FA8-ECFDD41CB7D1Q34864615-C464D634-8A35-407A-AA63-BCCB2ACD6E62Q34990860-F6EF1030-F245-4B84-B28C-DDD1BA66EAF6Q35837765-F6DF6EA3-B33C-4FFE-AFA3-E67A1FA931A7Q35861251-A29E2BD1-A9C5-43AB-8641-3C81958F393BQ36328978-6CDBCE11-9895-45D1-8AF3-7910DDD410D0Q36528561-985B9ADA-61F5-413C-99EE-5DAF31840F82Q37347740-DB867066-DBDA-42BA-9BAE-968457D2F918Q37505405-6B6C5901-19A1-4DFB-8FC6-484CA054584DQ37639093-F832093B-88A0-49AB-AE69-EA25F0D2C8A7Q38081966-866FE3B6-E173-4AA0-A900-200E76AF84F9Q38086871-32518E57-C44B-42C0-8CA5-E1D95773A93EQ38635596-2B8EE53F-B955-4CFE-8E33-E2D6939D7FF9Q38671575-AE4A4F1E-9BD2-4649-8D70-BF5EE9ED0864Q39261291-4215A09D-BCE9-4410-A3A8-6DFE94FB1C9DQ40866024-473516C7-03CD-422F-BA7D-DAC50E9DCF56Q40922357-4CDE7CD9-EDFB-4841-8B76-622491CDD3A2Q41189348-D05B4023-1F8A-45D1-9186-73E309931C56Q42182831-E2EBD1B1-6AAF-4ADB-B11D-E6455AD90D34Q47375197-C41CCBD4-7A5D-4067-BA5B-E206A98BE7C4Q47569740-D79EE3A4-C187-4F96-B291-2FDFF1E219D9Q55215825-775E50CF-4D86-4C53-9B0E-7436EE9F3D0A
P2860
Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Advances in hepatitis C virus ...... e formulations and modalities.
@en
Advances in hepatitis C virus ...... e formulations and modalities.
@nl
type
label
Advances in hepatitis C virus ...... e formulations and modalities.
@en
Advances in hepatitis C virus ...... e formulations and modalities.
@nl
prefLabel
Advances in hepatitis C virus ...... e formulations and modalities.
@en
Advances in hepatitis C virus ...... e formulations and modalities.
@nl
P2860
P1476
Advances in hepatitis C virus ...... e formulations and modalities.
@en
P2093
Farzin Roohvand
Niloufar Kossari
P2860
P304
P356
10.1517/13543776.2012.673589
P407
P577
2012-03-29T00:00:00Z